title: Effect of inhibitors of alpha-naphthylisothiocyanate-induced hepatotoxicity on the in vitro metabolism of alpha-naphthylisothiocyanate.
abstract: The role of S-oxidation in the toxic bioactivation of alpha-naphthylisothiocyanate (ANIT) was investigated. The effects of several thione compounds, inhibitors and an inducer of the cytochrome P-450-dependent mixed function oxidase systems on the in vitro metabolism of ANIT and aminopyrine were determined. Ethionamide, sodium diethyldithiocarbamate (Na-DDTC) and S-methyl diethyldithiocarbamate (Me-DDTC), three agents known to undergo metabolism by an S-oxidative pathway and diminish ANIT's toxicity, inhibited the in vitro enzymatic metabolism of ANIT by rat liver microsomes. Methimazole failed to alter either the hyperbilirubinemic response of ANIT or the in vitro metabolism of ANIT. All four thione compounds (i.e., ethionamide, Me-DDTC, Na-DDTC and methimazole) inhibited the enzymatic metabolism of aminopyrine by rat liver microsomes. Me-DDTC was the most potent, whereas methimazole was the least potent inhibitor of aminopyrine metabolism. Phenobarbital, which potentiates, and SKF-525A, which inhibits the hepatotoxicity of ANIT in vivo, correspondingly stimulated or inhibited the NADPH-dependent metabolism of ANIT and aminopyrine by liver microsomes. N-Decylimidazole (NDI), another classical inhibitor of cytochrome P-450-dependent monooxygenase system, inhibited both the in vivo toxicity and in vitro metabolism of ANIT. NDI also diminished the enzymatic metabolism of aminopyrine by liver microsomes. Thus the results of this study indicate that metabolism of ANIT is intimately related to its toxicity and that ANIT probably undergoes its toxic bioactivation via a cytochrome P-450-dependent S-oxidative pathway.
authors.forename: G J
authors.initials: GJ
authors.lastname: Traiger
authors.forename: K P
authors.initials: KP
authors.lastname: Vyas
authors.forename: R P
authors.initials: RP
authors.lastname: Hanzlik
mesh_terms: D015058:1-Naphthylisothiocyanate / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000633:toxicity; D000284:Administration, Oral; D000632:Aminopyrine / Q000378:metabolism; D000818:Animals; D001663:Bilirubin / Q000097:blood; D001711:Biotransformation; D002849:Chromatography, Gas; D004050:Ditiocarb / Q000494:pharmacology; D005000:Ethionamide / Q000494:pharmacology; D006932:Hyperbilirubinemia / Q000139:chemically induced; D007093:Imidazoles / Q000494:pharmacology*; D007700:Kinetics; D008297:Male; D008713:Methimazole / Q000494:pharmacology*; D008862:Microsomes, Liver / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D006899:Mixed Function Oxygenases / Q000378:metabolism; D009249:NADP / Q000378:metabolism; D010634:Phenobarbital / Q000494:pharmacology; D011335:Proadifen / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D013861:Thiocyanates / Q000378:metabolism*
chemical_list: D007093:Imidazoles; D013861:Thiocyanates; D000632:Aminopyrine; C044468:N-decylimidazole; D009249:NADP; D015058:1-Naphthylisothiocyanate; D008713:Methimazole; D004050:Ditiocarb; D011335:Proadifen; D006899:Mixed Function Oxygenases; D005000:Ethionamide; D001663:Bilirubin; D010634:Phenobarbital